Efficacy of Compound Betamethasone Injection Combined With Ropivacaine in Ultrasound-guided Intercostal Nerve Block for Chronic Post-thoracotomy Pain

Efficacy of Compound Betamethasone Injection Combined With Ropivacaine in Ultrasound-guided Slit Intercostals Nerve Block for Chronic Post-thoracotomy Pain:A Single Blind Randomized Control Trial

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05556122

Enrollment

100

Registered

2022-09-27

Start date

2022-07-04

Completion date

2022-12-30

Last updated

2022-09-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nerve Block

Brief summary

The patients were divided into two groups by random number method: GroupRD1 group and GroupRD2 group were given general anesthesia and intercostal nerve block.The drug for intercostal nerve block was 0.33% ropivacaine +2.333mg compound betamethasone (1.667mg betamethasone dipropionate + 0.667mg betamethasone sodium phosphate) to 15ml.

Detailed description

The RD1 group received ultrasound-guided intercostal nerve block at the incision before anesthesia induction, and the RD2 group received ultrasound-guided intercostal nerve block at the lateral costal Angle before anesthesia induction.

Interventions

OTHERintercostal nerve block

General anesthesia and intercostal nerve block were performed. The drug for intercostal nerve block was 0.33% ropivacaine +2.333mg compound betamethasone (1.667mg betamethasone dipropionate + 0.667mg betamethasone sodium phosphate) to 15ml

OTHERlateral intercostal nerve block

lateral intercostal nerve block

DRUGropivacaine + compound betamethasone

The drug for intercostal nerve block was 0.33% ropivacaine +2.333mg compound betamethasone (1.667mg betamethasone dipropionate + 0.667mg betamethasone sodium phosphate) to 15ml

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

1. 18-70 years old 2. ASA grade I-III 3. BMI: 18.5-28kg/m2 4. Type of surgery: elective thoracoscopic lung mass resection 5. Informed consent has been signed by the patient and/or family members

Exclusion criteria

1. game anesthesia or sugar cortical hormone drugs allergic 2. preoperative use of opioid medicines 3. serious blood coagulation dysfunction 4. serious heart, lung, liver and renal insufficiency 5. put, chemotherapy, and glucocorticoid immunosuppressive therapy history or diseases of the immune system 6. peptic ulcer 7. newly gastrointestinal surgery 8. has a history of thoracic surgery 9. is the central nervous system disease 10. Other glucocorticoids should be used with caution in patients such as fractures, wound repair, corneal ulcers, hyperadrenocortical disease, diabetes mellitus, pregnant women, etc.

Design outcomes

Primary

Measure	Time frame	Description
Acute and chronic postoperative pain	6 hours after surgery	Numeric rating scale(NRS) is used to assess acute postoperative pain

Countries

China

Contacts

Primary ContactYiBin Qin

572537172@qq.com13815212600

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026